Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4588691 | 0.98 | DNM1 (0.48) | DNM1MAOBS1PR2S1PR1S1PR3 | |
| SCHEMBL8168522 | 0.98 | DNM1 (0.48) | DNM1MAOBS1PR2S1PR1S1PR3 | |
| SCHEMBL4587698 | 0.98 | DNM1 (0.48) | DNM1MAOBS1PR2S1PR1S1PR3 | |
| SCHEMBL3506846 | 0.98 | DNM1 (0.48) | DNM1MAOBS1PR2S1PR1S1PR3 | |
| Hydrochloric Acid SCHEMBL5618261 | 0.96 | DNM1 (0.50) | DNM1MAOBS1PR2S1PR1S1PR3 | |
| SCHEMBL332286 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL5617623 | 0.91 | HPGD (0.41) | MAOBNPC1ALDH1A1CYP1A2CYP3A4 | |
| Oxalic Acid SCHEMBL5618292 | 0.88 | MAOB (0.47) | MAOBS1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL7048097 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL8665208 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531181-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | Pharma Two B Ltd. (IL) | 2012-12-12 | — | — | EP | claimed |
| US-20120301542-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD. (IL) | 2012-11-29 | — | — | US | claimed |
| WO-2011095973-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD. (IL) | 2011-08-11 | — | — | WO | claimed |
| US-20100267736-A1 | METHODS AND COMPOSITIONS TO ENHANCE THE EFFICACY OF PHOSPHODIESTERASE INHIBITORS | THOMAS THOMAS N | 2010-10-21 | — | — | US | claimed |
| US-20100267735-A1 | METHODS AND COMPOSITIONS TO ENHANCE THE EFFICACY OF PHOSPHODIESTERASE INHIBITORS | THOMAS THOMAS N | 2010-10-21 | — | — | US | claimed |
| EP-1686973-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RES & DEV FOUNDATION (IL) | 2009-03-25 | — | — | EP | claimed |
| EP-1942881-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL FAILURE | Technion Research and Development of Foundation, Ltd. (IL) | 2008-07-16 | — | — | EP | claimed |
| US-20080090915-A1 | METHOD FOR PREVENTING OR ATTENUATING ANTHRACYCLINE-INDUCED CARDIOTOXICITY | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2008-04-17 | — | — | US | claimed |
| WO-2007039909-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL FAILURE | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2007-04-12 | — | — | WO | claimed |
| US-20070082958-A1 | Methods for treatment of renal failure | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2007-04-12 | — | — | US | claimed |
| US-20060287401-A1 | Methods for treatment of cardiovascular disorders and diseases | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2006-12-21 | — | — | US | claimed |
| EP-1686973-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. (IL) | 2006-08-09 | — | — | EP | claimed |
| US-20050171210-A1 | Compositions and methods for treatment of cardiovascular disorders and diseases | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2005-08-04 | — | — | US | claimed |
| WO-2005051371-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2005-06-09 | — | — | WO | claimed |
| US-20050009835-A1 | Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors | THOMAS THOMAS NADACKAL (US) | 2005-01-13 | — | — | US | claimed |
| EP-0573498-B1 | ALIPHATIC PROPARGYLAMINES AS SELECTIVE MAO-B INHIBITORS AND AS NEUROPROTECTIVE AGENTS | UNIV SASKATCHEWAN (CA) | 1998-11-18 | — | — | EP | claimed |
| EP-4603095-A2 | IMPROVED PHARMACEUTICAL FORMULATIONS | Ferring B.V. (NL) | 2025-08-20 | — | — | EP | disclosed |
| EP-3787596-B1 | IMPROVED PHARMACEUTICAL FORMULATIONS | FERRING BV (NL) | 2025-06-25 | — | — | EP | disclosed |
| WO-1996037226-A2 | COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS | PFIZER INC. (US) | 1996-11-28 | — | — | WO | disclosed |
| WO-1996026720-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOAMINE OXIDASE B INHIBITORS | R.P. SCHERER LIMITED (GB) | 1996-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009835-A1 | Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors | PDE3A, PDE3B, PDE5A | DNM1 2274/4885MAOB 13/4885S1PR2 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.